干扰素联合索拉非尼治疗晚期肾癌临床效果及安全性评价.docVIP

干扰素联合索拉非尼治疗晚期肾癌临床效果及安全性评价 　　[摘要] 目的 探讨干扰素联合索拉非尼治疗晚期肾癌的临床效果及安全性评价。 方法 抽取2013年6月～2014年6月期间延安大学附属医院门诊收治的晚期肾癌患者72例。根据治疗方法的不同分为索拉非尼组和联合组，索拉非尼组患者42例，联合组患者30例。索拉非尼组患者给予索拉非尼连续用药方案，联合组患者在索拉非尼组的基础上加用干扰素，对比两组临床有效率、疾病控制率、无进展生存期（PFS），总生存期（OS）、不良反应发生率。 结果 索拉非尼组患者中位PFS为16个月；部分缓解和稳定患者的中位PFS可以达28个月；有23例患者死亡，平均OS 12个月；1年生存率73.81%，2年生存率42.86%，3年生存率19.05%。联合组无疾病进展和死亡病例，疾病控制率100%；中位PFS为15个月。联合组临床有效率稍高于索拉非尼组，但差异无统计学意义（P 0.05）；联合组的疾病控制率明显高于索拉非尼组，差异有统计学意义（P 0.05）。 结论 索拉非尼对晚期肾癌的治疗效果较好，加入干扰素配合治疗不仅可以提高疾病缓解率，而且不增加毒副反应的发生率；两组患者出现的不良反应均可耐受，临床应用较为安全。 　　[关键词] 肾癌；晚期；索拉非尼；无进展生存期；缓解；毒副反应 　　[中图分类号] R737.11 [文献标识码] A [文章编号] 1673-7210（2016）06（c）-0161-04 　　[Abstract] Objective To discuss the clinical efficacy and safety evaluation of patients with advanced renal cell carcinoma by using interferon combined with sorafenib. Methods 72 cases of patients with advanced renal cell carcinoma in the Outpatient Department of Yanan University Affiliated Hospital from June 2013 to June 2014 were selected. According to the different treatment methods， 72 cases of patients were divided into sorafenib group and joint group. There were 42 cases of patients in the sorafenib group， while 30 cases in the joint group. The patients in the sorafenib group were treated with direct sorafenib， while those in the joint group received sorafenib combined with interferon. The clinical efficiency， disease control rate， progression free survival （PFS）， overall survival （OS） and the incidence of adverse reactions were compared between the two groups. Results The median PFS of patients in the sorafenib group was 16 months. The median progression free survival of patients with partial remission and stability could be up to 28 months. There were 23 patients died in the sorafenib group and the mean OS was 12 months. The 1 year survival rate was 73.81%， the 2 year survival rate was 42.86% and the 3 year survival rate was 19.05% in the sorafenib group. There were no disease progression and death in the joint group. The median PFS of p